Semaglutide 2.4mg for Low Responders After Bariatric Surgery
Launched by ZUYDERLAND MEDISCH CENTRUM · Feb 22, 2024
Trial Information
Current as of August 19, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at the effectiveness of a medication called semaglutide for people who have not lost enough weight after having bariatric surgery. Bariatric surgery helps many people lose weight, but about 20-30% of patients, known as low responders, do not achieve satisfactory weight loss. Instead of undergoing additional surgeries, which can carry higher risks, this study is exploring whether taking semaglutide can help these patients lose more weight and improve their overall health.
To participate in this trial, individuals need to meet certain criteria. They should have had a body mass index (BMI) of 35 or higher before surgery and have undergone a specific type of weight-loss surgery, such as gastric bypass or sleeve gastrectomy. They also need to be in the lowest weight loss category three months after their surgery. Participants will be closely monitored and may receive group consultations to support their journey. It's important to note that individuals with certain health conditions, like severe heart or kidney issues, or those who are pregnant or breastfeeding, will not be eligible to join.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • BMI before surgery was ≥ 35.0 kg/m2
- • Patient is treated with group consultation at the NOK
- • Patient has undergone a primary (banded) RYGB or (banded) sleeve gastrectomy (SG)
- • Patient is in the lowest %TWL quartile, 3 months after surgery and will be enrolled in the plus module.
- Exclusion Criteria:
- • Gastropareses or gastro-intestinal complaints after bariatric surgery
- • Type 1 or type 2 diabetes and/or diabetic retinopathy
- • Decreased renal function (creatinine clearance \< 30 ml/min)
- • Liver failure (all)
- • Congestive heart failure or angina pectoris NYHA class III and IV
- • Malignancy in history
- • Pancreatitis (in history)
- • (expected) Pregnancy / breast-feeding
- • Inflammatory Bowel Disease
- • Thyroid malignancy in history
- • Use of warfarin or other coumarin derivates
About Zuyderland Medisch Centrum
Zuyderland Medisch Centrum is a leading healthcare institution in the Netherlands, renowned for its commitment to advancing medical research and improving patient care. With a multidisciplinary approach, the center integrates innovative clinical trials into its healthcare services, fostering collaboration among specialists to explore new therapies and treatment modalities. Zuyderland Medisch Centrum prioritizes patient safety and ethical standards in all research endeavors, aiming to contribute valuable insights to the medical community and enhance health outcomes for diverse populations. Through its state-of-the-art facilities and a dedicated team of researchers and clinicians, the center strives to remain at the forefront of medical advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Jan Willem Greve, prof
Principal Investigator
Zuyderland Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported